We want to hear about your efforts to enhance quality, care delivery, and the patient experience. Share your innovative project, program or best practice!
Poster Presentation Authors of accepted abstracts will be invited to present a virtual poster on Saturday, March 23, 2024. Podium Presentation Three abstracts will be selected for oral presentations on Saturday, March 23, 2024. The responsible first author will receive a $250 stipend. Selected Areas/Topics: Topics centered around the theme of New Horizons in Survivorship are strongly encouraged.Abstracts Guidelines:
Podium Consideration Submission Deadline: Friday, January 19, 2024. Poster Consideration Submission Deadline: Friday, February 23, 2024. Contact Information Your name, institution, address, telephone number, fax number, and eĀmail address. As the First Author (presenter), you will receive all future correspondence from NNECOS. | Abstract Title The title of your abstract in sentence case, capitalizing only the first letter of the first word of the title and any proper nouns or acronyms. Do not use proprietary drug names in the title; use generic drug names instead. Do not refer to study results or conclusions in the title; it should objectively describe the study. NNECOS reserves the right to edit abstract titles to conform to this policy. Coauthor(s) The name and institution of each coauthor. Disclosure Declaration Abstract submissions must be accompanied by an abstract disclosure form for all authors. File attachments should be uploaded at the time of submission. RESPONSIBILITIES OF THE FIRST AUTHOR The First Author must
|
CONFLICT OF INTEREST POLICY
NNECOS must ensure fair balance, independence, objectivity, and scientific rigor in all of its educational activities through appropriate disclosure of financial interests, among other things. The following interests or relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships at the time of submission.